CWM
VRNA

Cahill Wealth Management’s Verona Pharma VRNA Stock Holding History

Cahill Wealth Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$512K Buy
8,060
+315
+4% +$18.8K 0.26% 37
2024
Q4 		$360K Hold
7,745
– – 0.18% 41
2024
Q3 		$223K Buy
+7,745
New +$191K 0.12% 48
2023
Q4 		– Sell
-10,445
Closed -$170K – 47
2023
Q3 		$170K Sell
10,445
-1,600
-13% -$30.8K 0.13% 46
2023
Q2 		$255K Hold
12,045
– – 0.18% 39
2023
Q1 		$242K Buy
12,045
+2,295
+24% +$49.6K 0.18% 42
2022
Q4 		$218K Buy
+9,750
New +$130K 0.16% 45

Other funds holding VRNA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cahill Wealth Management's VRNA Position: Q1 2025 in Review

Cahill Wealth Management increased its Verona Pharma (VRNA) stake by 4.1% in Q1 2025, buying an estimated $18.8K and bringing the position to 8,060 shares worth $512K. The position accounts for 0.26% of the portfolio, ranked #37.

Cahill Wealth Management first reported a position in VRNA in Q4 2022 and has held it in 7 quarters since. 258 funds tracked by Wall St. Rank hold VRNA as of Q1 2025.

  • Cahill Wealth Management held 8,060 shares of Verona Pharma worth $512K as of Q1 2025.
  • Cahill Wealth Management bought 315 Verona Pharma shares in Q1 2025, an estimated $18.8K.
  • Verona Pharma made up 0.26% of Cahill Wealth Management's portfolio in Q1 2025, its #37 holding.
  • Cahill Wealth Management first reported a position in Verona Pharma in Q4 2022 and has held it in 7 quarters since.
  • 258 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2025.

Based on Cahill Wealth Management's 13F filing for Q1 2025, filed 12 May 2025.